ESG Report 2023

6.2.1 Medical Ethics The Group has established a clinical research centre. As a quality control system covering the entire process of clinical trials, the centre is mainly responsible for the clinical development strategy and path formulation, research protocol design, clinical trial organization and implementation, project management and monitoring, quality control and other related work for all clinical trial projects of the Group. During the reporting period, all clinical trials of the Group strictly complied with the “Declaration of Helsinki of the World Medical Association”, the “Civil Code of the People's Republic of China”, the “Drug Administration Law of the People's Republic of China”, “Measures for the Administration of Drug Registration”, “Quality Control of Clinical Trials of Drugs” and “Measures for Ethical Review of Life Sciences and Medical Research Involving Humans” principles and related ethical requirements, taking the rights and safety of subjects as the primary concern in drug clinical trials. We require all drug clinical trials to obtain a clinical trial license, develop scientific, ethical, compliant and practical clinical trial protocols and work plans, including but not limited to project management plan, inspection plan, data management plan and risk control plan, and set clear provisions for reviewing, verifying and tracing original data, frequency and requirements of inspections, collaborative monitoring, auditing, etc. Clinical trials shall ensure all subjects sign the informed consent forms through examination by the drug clinical trial institution and ethics committee. Regarding the personal information security of the subjects, we has always adhered to the purpose of strictly protecting the data security of the subjects. We ensure the confidentiality of the research project data through confidentiality measures such as anonymization or coding, and prevent the harm and risks caused by the leakage of the subjects' privacy. The Group is currently conducting 10 clinical trials for chemical and biological innovative drugs as well as biosimilars. Besides, clinical trials of several innovative drugs and biosimilars are about to start. In the process, we will realise continuous monitoring, inspection, feedback and improvements of the quality of clinical trials to ensure the quality of clinical trials. 6.2.2 Bui ding a Culture of Integrity l The development of The United Laboratories is inseparable from the sincere support of all partners. The Group advocates the business principles of friendship, equality and mutual development, and expects to establish a fair and just cooperative relationship with all partners. We believe that commercial bribery not only violates the law, but also violates basic business principles, disrupts the market economic order, brings about unfair competition and waste of resources, hinders the healthy development of both parties and seriously affects both parties' credibility in their respective industries. Thus, the Group has always upheld the principles of business ethics and gave primacy to integrity so as to ensure that the business operates in compliance. At the same time, commercial bribery also fuels corrupt practices, triggers economic crimes, and corrodes the foundations of corporate employees and corporate development. Therefore, we expect employees and partners to abide by the law and strictly adhere to principles of business ethics, and hereby we make the following statement: 28 Environmental, Social and Governance Report 2023 The United Laboratories International Holdings Limited